Skip to main content

Table 2 Adverse events by treatment group

From: Favorable efficacy of rituximab in ANCA-associated vasculitis patients with excessive B cell differentiation

Variables

Rituximab group, n = 34

IV-CY group, n = 20

p value

All adverse events, no.

19

14

0.39

Death, no

4

4

0.45

Sepsis (pyelonephritis)

Bacterial pneumonia

 

Invasive pulmonary aspergillosis

PCP + invasive pulmonary aspergillosis

 

Bacterial pneumonia

Invasive pulmonary aspergillosis

 

Stroke

Sepsis (bacterial pneumonia)

 

Leukopenia, no

4

4

0.45

Thrombocytopenia, no

4

2

1.00

Severe infection, no

11

12

0.09

CMV infection, n = 2

PCP

 

Bacterial pneumonia, n = 2

CMV infection, n = 2

 

Legionella pneumonia

Acute cholangitis

 

Sepsis (pyelonephritis)

Tuberculosis

 

Invasive pulmonary aspergillosis

PCP + invasive pulmonary aspergillosis

 

PCP

Bacterial pneumonia, n = 4

 
 

Invasive pulmonary aspergillosis

 
 

Sepsis (bacterial pneumonia)

 

VTE, no

1

0

0.37

  1. The statistical difference was determined by chi-square test. Difference with p < 0.05 was considered significant
  2. PCP pneumocystis pneumonia, CBV cytomegalovirus, VTE venous thromboembolism